(3R,4aR,6R,6aS,10aS,10bR)-3-ethenyl-6-hydroxy-3,4a,7,7,10a-pentamethyl-2,5,6,6a,8,9,10,10b-octahydrobenzo[f]chromen-1-one | 121817-29-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (3R,4aR,6R,6aS,10aS,10bR)-3-ethenyl-6-hydroxy-3,4a,7,7,10a-pentamethyl-2,5,6,6a,8,9,10,10b-octahydrobenzo[f]chromen-1-one
• CAS: 121817-29-6
• 化学式: C₂₀H₃₂O₃
• 分子量: 320.5
• InChiKey: QSBSWAUSLLQUDV-FCZHJMSUSA-N

物化性质

• 熔点：
  119-120 °C(Solv: chloroform (67-66-3))
• 沸点：
  412.7±45.0 °C(Predicted)
• 密度：
  1.060±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• PHOSPHODIESTERASE INHIBITORS FOR TREATING TASTE AND SMELL DISORDERS
  申请人：Henkin, Robert I.

  公开号：EP2968204B1

  公开（公告）日：2019-05-15
• PHOSPHODIESTERASE INHIBITOR TREATMENT
  申请人：HENKIN Robert I

  公开号：US20160030435A1

  公开（公告）日：2016-02-04

  Methods and compositions are disclosed for the treatment of taste and smell disorders. The compositions comprise phosphodiesterase inhibitors and are formulated for intranasal administration.
• Phosphodiesterase Inhibitor Treatment
  申请人：Cyrano Therapeutics, Inc.

  公开号：US20220226332A1

  公开（公告）日：2022-07-21

  Methods and compositions are disclosed for the treatment of taste and smell disorders. The compositions comprise phosphodiesterase inhibitors and are formulated for intranasal administration.